Nonparametric goodness-of-fit testing for parametric covariate models in pharmacometric analyses

CPT Pharmacometrics Syst Pharmacol. 2021 Jun;10(6):564-576. doi: 10.1002/psp4.12614. Epub 2021 Jun 4.

Abstract

The characterization of covariate effects on model parameters is a crucial step during pharmacokinetic/pharmacodynamic analyses. Although covariate selection criteria have been studied extensively, the choice of the functional relationship between covariates and parameters, however, has received much less attention. Often, a simple particular class of covariate-to-parameter relationships (linear, exponential, etc.) is chosen ad hoc or based on domain knowledge, and a statistical evaluation is limited to the comparison of a small number of such classes. Goodness-of-fit testing against a nonparametric alternative provides a more rigorous approach to covariate model evaluation, but no such test has been proposed so far. In this manuscript, we derive and evaluate nonparametric goodness-of-fit tests for parametric covariate models, the null hypothesis, against a kernelized Tikhonov regularized alternative, transferring concepts from statistical learning to the pharmacological setting. The approach is evaluated in a simulation study on the estimation of the age-dependent maturation effect on the clearance of a monoclonal antibody. Scenarios of varying data sparsity and residual error are considered. The goodness-of-fit test correctly identified misspecified parametric models with high power for relevant scenarios. The case study provides proof-of-concept of the feasibility of the proposed approach, which is envisioned to be beneficial for applications that lack well-founded covariate models.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aging / metabolism
  • Algorithms
  • Antiviral Agents / pharmacokinetics
  • Child
  • Computer Simulation
  • Humans
  • Metabolic Clearance Rate
  • Models, Biological*
  • Models, Statistical*
  • Palivizumab / pharmacokinetics
  • Statistics, Nonparametric

Substances

  • Antiviral Agents
  • Palivizumab